Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Welcome to Slider's Dugout -- Ignore unavailable to you. Want to Upgrade?

To: tntpal who wrote (36227)	1/19/2022 3:01:01 PM
From: tntpal	2 Recommendations Recommended By DinoNavarre Winfastorlose Read Replies (1) \| Respond to of 50526

Researchers testing COVID-19 vaccine patch... Researchers began testing a new COVID-19 vaccine patch this month that they hope will provide long-lasting protection against the virus. On Wednesday, researchers said the PepGNP-Covid19 vaccine is in an early-study phase, as the technology is much different than the Moderna or Pfizer-BioNTech coronavirus vaccines, Reuters reported. Instead of producing an antibody response, the vaccine patch focuses on cellular immunity by targeting T-cells that could eliminate the coronavirus and prevent it from spreading in the body. he vaccine works by putting a patch with microneedles on a person then taking it off. "With this new vaccine that generates this cellular immunity we hope to have a longer period of protection ... we don't know yet, but it could be one year, two years, three years," professor Blaise Genton, head of the study, told Reuters... thehill.com